InflaRx(IFRX)
JENA, GermanyBiotechnology
Focus: InflaRx is a German-based public biotech focused on developing monoclonal antibodies targeting the complement C5a pathway for inflammatory and immunological diseases. The company is publicly traded on Nasdaq (IFRX) and recently raised $140M to fund its pipeline through 2029.
Profile data last refreshed 12h ago · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Open Jobs
0
About InflaRx
AI assessmentNot HiringNo open roles listed right now. Follow InflaRx to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from InflaRx's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Data completeness
3/9 — Basic
Company HealthSolid
Pipeline
Mid-stage
1 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
CaCP29, a humanized monoclonal antibody
Drug SafetyClinical Trials (1)
NCT01319903Clinical Assessment of Safety and Tolerability of the New Monoclonal Humanized Antibody CaCP29
Phase 1Help build intelligence for InflaRx
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.